11-19-06

Express Mail Label No.: EV 869861412 US Pate of Deposit: November 27, 2006

Attorney Docket No.: 24492-01071 NATL

NOV 2 7. 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Brand et al.

SERIAL NUMBER:

10/555,049

Not Yet Assigned

INTERNATIONAL

April 30, 2004

EXAMINER: ART UNIT:

Not Yet Assigned

FILING DATE:

For:

COMBINED USE OF KERATINOCYTE GROWTH FACTOR

AGONISTS AND GASTRIN COMPOUNDS

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (1 page), in duplicate;
- 2. Modified Form 1449/PTO (2 pages), in duplicate;
- 3. Copies of Cited References: B1-2; C1-22; and
- Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24492-007 NATL. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully supmitted

Vor R. Elnfi, Reg. No. 39,529 David E. Johnson, Reg. No. 41,874

Attorney(s) for Applicants

MINTZ, LÉVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623 Tel: (617) 542-6000

Fax: (617) 542-2241

Date: November 27, 2006

TRA 2225399v.1

Attorney Docket No.: 24492-007 NATL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANTS:

Brand et al.

SERIAL NUMBER:

10/555,049

EXAMINER:

Not Yet Assigned

INTERNATIONAL

April 30, 2004

ART UNIT:

Not Yet Assigned

FILING DATE:

For:

COMBINED USE OF KERATINOCYTE GROWTH FACTOR

AGONISTS AND GASTRIN COMPOUNDS

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are enclosed.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A3 are not submitted. However, please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-031 Reference No. 24492-007 NATL.

Respectfully submitted

No. 39,529

David E. Johnson, Reg. No. 41,874

Attorneys for Applicants

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623 Tel: (617) 542-6000

Fax: (617) 542-2241

Date: November 27, 2006

Express Mail No.: EV 869861412 US Page 1 of 2 Date of Deposit: November 27, 2006 Attorney Docket No.: 24492-007 NATL

e type a plus sign (+) in this box

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

dified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/555,049
International Filing Date	April 30, 2004
First Named Inventor	Brand
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	24492-007 NATL

				U.S. PATENT DOCUMENTS			
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	5,858,977	01/12/99	Aukerman, et al.	514	12	
	*A2	5,885,956	03/23/99	Nardi, et al.	514	2	
	*A3	6,288,301 B1	09/11/01	Nardi, et al.	800	18	

		Tall and the second		FOREIGN PATENT DOCUMENTS		
Exam Initials	Cite No.	Foreig Office	n Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	Bl	wo	90/08771	RUBIN ET AL.	08/09/90	
	B2	Wo	00/44400	RTP PHARMA INC.; THE GENERAL HOSPITAL CORPORATION	08/03/00	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.			
	C1	Bonner-Weir, et al. (2000) Proc. Natl. Acad. Sci. U.S.A., 97:7999-8004.			
	C2	Holstad, et al. (1999) J. Endocrinol., 163:229-234.			
	C3	Krakowski, et al. (1999) Am. J. Pathol., 154:683-691.			
,	C4	Logothetopoulos, J. (1972) in Handbook of Physiology (Am. Physiol. Soc., Washington, D.C.), <i>Endocrinology</i> , Section 7, Chapter 3, pgs. 67-76.			
	C5	Logsdon, et al. (1997) Gastroenterology, 112:A458.			
	C6	Lu, et al. (1999) <i>Diabetes</i> , <u>48</u> :A236.			
	C7	Nielsen, et al. (1999) J. Mol. Med., 77:62-66.			
	C8	Okamoto, H. (1999) J. Hepatobiliary Pancreat Surg., 6:254-262.			
	C9	Pierce, et al. (1994) J. Exp. Med., <u>179</u> :831-840.			
	C10	Playford, et al. (1998) J. Pathol., <u>184</u> :316-322.			
	C11	Powers, et al. (2000) Endocrine-Related Cancer, 7:165-197.			
	C12	Rafaeloff, et al. (1997) J. Clin. Invest., 99:2100-2109.			
	C13	Sharma, et al. (1999) Diabetes, <u>48</u> :507-513.			
	C14	Staiano-Coico, et al. (1993) J. Exp. Med., <u>178</u> :865-878.			
	C15	Stauffacher, et al. (1970) Proc. Soc. Exp. Biol. Med., 133:194-200.			
	C16	Veves, et al. (2001) J. Clin. Invest., 107:1215-1218.			
	C17	Wang, et al. (1993) J. Clin. Invest., 92:1349-1356.			
	C18	Wang, et al. (1995) Am. J. Physiol., 268:G1025-G1036.			
	C19	Xu, et al. (1999) Diabetes, 48:2270-2276.			

Date of Deposit: November 27, 2006
NOV 2 7 2006

Page 2 of 2 Attorney Docket No.: 24492-007 NATL

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
am Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	
	C20	Yamamoto, et al. (2000) Diabetes, 49:2021-2027.	
	C21	Yamaoka, et al. (1999) Int. J. Mol. Med., 3:247-261.	
	C22	Yamasaki, et al. (1996) J. Biol. Chem., 271:15918-15921	

^{*} By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A3 are not submitted.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ADM 1210594v.1